🔗 Share this article

As the United States continues making historic changes to its vaccination recommendations, a particular individual appears somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning Covid vaccinations in the global health crisis and has zeroed in on potential deaths following COVID-19 vaccination in her short time at the FDA.

Proposed Shifts to Pediatric Vaccine Schedule

Health officials were set to announce sweeping changes to the pediatric immunization program earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US to become more similar to Denmark, a country with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Background

The appointee has no apparent track record in medication creation, approval processes or management, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Former commissioners of CBER would “be deeply familiar with laws and regulations and the science of drug development”, commented Dr. Janet Woodcock. “Objectively, she lacks the kind of background that previous people who led the center have had.”

CDER has an vast workload at the agency, Woodcock pointed out.

“Everybody just pays attention on the new drug program, but the generic program approves numerous generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one must be looked after,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative element to the position, which supervises over 5,000 staff members. “It’s a enormous administrative position, if you do it right,” she added.

Official Statement and Disputed Policies

In response to questions about Dr. Høeg's fitness for the role and whether this selection represents more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “questions rely on incorrect assumptions”.

“Her resume aligns with the responsibilities of her position,” the spokesperson explained, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a disputed expedited therapy clearance system that allegedly worried her predecessors. “By what process are these drugs being chosen for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There is a lot of secrecy happening at the agency right now.”

Overall, he stated, “the FDA looks to be trending towards more relaxed oversight of most medications, aside from immunizations.”

Established Past Work on Immunizations

With immunizations, Dr. Høeg has a more established, if troubling, past, some experts said. She authored a analysis using non-validated crowd-sourced reports to assess the rate of heart inflammation after Covid immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the incoming government featured changing regulations for novel immunizations and ending “unnecessary” vaccines, she stated after the election on a audio program. At the FDA, Dr. Høeg has according to sources suggested excluding young men from obtaining Covid vaccines.

“She is an thorough ideologue who starts off with her beliefs and works backwards to retrofit the evidence in a very deceptive, dishonest fashion,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other skeptics, {like|